Showing results (1-10 of 143) with videos related to
Sort By:
Pageof 15
Clinical Pharmacology and Therapeutics|January 12, 2017
Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing ScienceG M Blumenthal, K B Goldberg, R PazdurAnnals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2019
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancerG M Blumenthal, Y Gong, K Kehl, et al.Oncology (Williston Park, N.Y.)|February 12, 1998
Phase I and pharmacokinetic evaluations of UFT plus oral leucovorinR PazdurClinical Pharmacology and Therapeutics|February 14, 2015
The role of nonrandomized trials in the evaluation of oncology drugsR Simon, G M Blumenthal, M L Rothenberg, et al.British Journal of Haematology|October 1, 1991
Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasmsR PazdurOncology (Williston Park, N.Y.)|September 3, 1998
Irinotecan: toward clinical end points in drug developmentR PazdurAnnals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapyC E McCoach, G M Blumenthal, L Zhang, et al.Journal of Surgical Oncology. Supplement|January 1, 1993
Systemic therapies for unresectable primary hepatic tumorsD Moore, R PazdurClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Thymidylate synthase inhibitorsN Touroutoglou, R PazdurPageof 15